Email this article The application of Ipilimumab in treatment of patients with metastatic melanoma
- Authors: Samoilenko I.V1, Harkevitch G.Y.1, Demidov L.V1
-
Affiliations:
- The N.N. Blokhin Russian oncologic national center
- Issue: Vol 21, No 1 (2015)
- Pages: 4-9
- Section: Articles
- URL: https://journals.rcsi.science/0869-2106/article/view/38227
- DOI: https://doi.org/10.17816/rmj38227
- ID: 38227
Cite item
Full Text
Abstract
The article presents intermediate results of analysis of effectiveness and tolerance of Ipilimumab applied within the framework of program of broadened access CA184-089 EAP. Ipilimumab is a new immune stimulator blocking receptors of CTLA4 om lymphocytes and regenerating anti-tumor immune response. The analysis covered 52 patients receiving treatment from October 2011 to August 2012 in the N.N. Blokhin Russian oncologic national center. The effectiveness of pharmaceutical corresponded to previously published data. The median of total survival in all population of patients made up to 13.7 months (confidence range 95% from 8.0 to 19.5 months). The six-moths total survival made up to 77.5±5.9%, one-year survival made up to 45.9±7.9%. No new undesirable occurrences were detected. Altogether, 9 severe undesirable occurrences were registered (from third to fifth degrees of severity according CTCAE V4.0) in seven patients (13.5%), one with lethal outcome (1.9%).
Full Text
##article.viewOnOriginalSite##About the authors
I. V Samoilenko
The N.N. Blokhin Russian oncologic national centerхирургическое отделение № 10 115478 Moscow, Russia
Galina Yu. Harkevitch
The N.N. Blokhin Russian oncologic national center
Email: gkharkevich@mail.ru
MD, PhD, Leading Researcher Dept. of Biotherapy 115478 Moscow, Russia
L. V Demidov
The N.N. Blokhin Russian oncologic national centerхирургическое отделение № 10 115478 Moscow, Russia
References
- Burnet M. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1957; 1(5022): 779-86.
- Dunn G.P. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002; 3(11): 991-8.
- Vesely M.D., Schreiber R.D. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. 2013; 1284: 1-5.
- Hodi F.S. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363(8): 711-23.
- Ribas A., Butterfield L.H., Economou J.S. Genetic immunotherapy for cancer. Oncologist. 2000; 5(2): 87-98.
- Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 2013; 19(19): 5300-9.
- Assi H., Wilson K.S. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr. Oncol. 2013; 20(2): e165-9.
- Delyon J. et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 2013; 24(6): 1697-703.
- Maio M. Survival amalysis with 5 years of follow up in phase III study of ipilimumab and dacarbazine in metastatic melanoma: ESMO oral presentation 3704. Eur. J. Cancer. 2013.
- Wolchok J.D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009; 15(23): 7412-20.
- Weber J.S. et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013; 119(9): 1675-82.
